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Abstract
Background: Prostatic artery embolisation (PAE) has been associatedwith an improvement of
lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH), but
conclusive evidence of efficacy from randomised controlled clinical trials has been lacking.
Objective: To assess the safety and efficacy of PAE compared with a sham procedure in the
treatment of LUTS/BPH.
Design, setting, and participants: A randomised, single-blind, sham-controlled superiority clini-
cal trial was conducted in 80males45 yr with severe LUTS/BPH refractory tomedical treatment
from2014 to 2019 in a private clinic,with efficacyassessments at 6 and12mo after randomisation.
One patient in the PAE group and three in the sham group did not complete the study.
Intervention: Patients were randomised 1:1 upon successful catheterisation of a prostatic
artery to either PAE or a sham PAE procedurewithout embolisation. After 6 mo, all 38 patients
randomised to the sham group who completed the single-blind period underwent PAE, and
both groups completed a 6-mo open period.
Outcome measurements and statistical analysis: An intention-to-treat analysis of all ran-
domised patients was performed. The coprimary outcomes were the change from baseline to
6 mo in the International Prostate Symptom Score (IPSS) and the quality of life (QoL) score at
6 mo, analysed with analysis of covariance and t test, respectively.
Results and limitations: Mean age was 63.8 6.0 yr, baseline IPSS 26.4  3.87, and QoL score
4.43 0.52.At6mo,patients in thePAEarmhadagreater improvement in IPSS,withadifference
in the change from baseline of 13.2 (95% confidence interval [CI] 10.2–16.2, p < 0.0001), and a
better QoL score at 6mo (difference: 2.13; 95% CI 1.57–2.68, p < 0.0001) than the patients in the
shamarm. The improvements in IPSS andQoL in the shamgroup 6mo after they performed PAE
were, respectively, 13.6  9.19 (p < 0.0001) and 2.05  1.71 (p < 0.0001). Adverse events
occurred in 14 (35.0%) patients after PAE and in 13 (32.5%) after sham, with one serious adverse
event in the sham group during the open period. No treatment failures occurred. Limitations
include a single-centre trial, only severe LUTS/BPH, and follow-up limited to 12 mo.
Conclusions: The improvements in subjective and objective variables after PAE are far super-
ior from those due to the placebo effect.
Patient summary: Clearly superior efficacy of prostatic artery embolisation (PAE) compared
with a sham procedurewas found in this study, which supports the use of PAE in patients with
typical symptoms associated with benign prostatic hyperplasia.
As© 2019 Europeany Deceased after trial end.
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Benign prostatic hyperplasia (BPH), a condition often
associated with lower urinary tract symptoms (LUTS), has
a prevalence rate of over 50% in men over 60 yr old, which
increases with age [1,2]. Medication such as alpha-blockers,
5-alphareductase inhibitors (5-ARIs), or both are usually the
first-line approach [3–6]. Other treatment options include
minimally invasive treatments, such as prostatic urethral
lift andwater vapour thermal therapy [7–13]. Prostatectomy
is the gold standard andmay be transurethral (transurethral
resection of the prostate [TURP]), if the prostate is smaller
than 80 cm3 [130_TD$DIFF], or by open surgery for larger prostates. Laser
enucleation, transurethral vaporisation of the prostate, and
photoselective vaporisation of the prostate may allow
endoscopic treatment when the prostate is larger than
80 cm3 [9,8–13].
Prostatic artery embolisation (PAE) is a minimally
invasive treatment that has been shown in many observa-
tional studies and meta-analyses to be safe and effective,
reducing LUTS/BPH [14–22]. In addition,many phase II trials
without controls already exist, showing the safety and
efficacy of PAE for BPH. However, LUTS/BPH is known to be
very susceptible to placebo treatments, and conclusive
demonstration of efficacy will require randomised con-
trolled trials, but until now only three randomised clinical
trials of PAE have been published, all comparative to TURP
and none has conclusively demonstrated the efficacy of PAE
in LUTS/BPH: a study in 107 patients did not find
statistically significant differences between TURP and PAE
at 12 and 24 mo in clinical and functional outcomes except
for a greater decrease in prostate volume (PV) in the TURP
group [23]; another study in 30 patients has shown a
greater effect of TURP at 12 mo in the International Prostate
Symptom Score (IPSS) and quality of life (QoL) scores and in
objective outcomes, but the trial design did not allow a
proof of PAE efficacy [24]; and a noninferiority trial of PAE to
TURP in 99 patients has shown superiority of TURP in
secondary outcomes at 3 mo (PV, maximum urine flow rate
[Qmax], and postvoid residual urine volume [PVR]), but was
inconclusive regarding noninferiority in clinical outcomes
[25]. Therefore, PAE is still at the investigational phase, as
evidence of efficacy compared with standard treatment has
not yet been clearly demonstrated and randomised place-
bo-controlled clinical trials have not previously been
conducted. The aim of this study was to assess the safety
and effect of PAE above and beyond the placebo effect
versus those of a sham procedure for the treatment of
patientswith severe LUTS/BPH not adequately controlled by
medical therapy with alpha-blockers.
2. Patients and methods
2.1. Study design
A single-centre, parallel-group, single-blind, randomised
clinical trial was conducted to test the superiority of PAE
versus a sham PAE procedure, consisting of a single-blind
phase with the primary efficacy analysis 6 mo afterrandomisation, followed by an open extension phase where
thepatients of the sham trial armcrossedover to thePAEarm
and a final evaluation was done 12 mo after randomisation.
The studywas conducted at Hôpital Saint Louis in Lisbon,
Portugal; the study protocol was approved by the in-house
Research Ethics Committee (approval numbers 7-2013/09/
24 [initial protocol] and 12-2016/04/21 [protocol amend-
ment]), and all patients gave written informed consent.
2.2. Patients
The inclusion criteria were as follows: males over 45 yr old;
diagnosis of LUTS/BPH based on clinical history, digital
rectal examination, urinalysis, transrectal ultrasound
(TRUS), and prostate-specific antigen (PSA); severe LUTS
defined, in a screening and in a baseline visit 2 wk apart, by
an IPSS of 20 and a QoL score of 3 after a minimum of 6-
mo treatment with alpha-blockers for LUTS/BPH; Qmax
<12 ml/s; PV  40 cm3; accepting the risk of developing
sexual dysfunction after treatment; and successful cathe-
terisation of one of the prostatic arteries (technical success).
The exclusion criteria were the following: computed
tomography (CT) angiography showing that prostatic
arteries were not feasible for PAE; previous surgical or
invasive prostate treatments such as TURP, transurethral
microwave therapy, transurethral needle ablation, laser, or
any other minimally invasive treatment; acute or chronic
prostatitis or suspected prostatitis including chronic pain,
intermittent pain, or abnormal sensation in the penis, testis,
anal, or pelvic area in the previous 12mo; history of prostate
or bladder cancer or pelvic irradiation; active or recurrent
urinary tract infections (more than one episode in the
previous 12 mo); history of neurogenic bladder or LUTS
secondary to neurologic disease; advanced atherosclerosis
and tortuosity of iliac and prostatic arteries; secondary
renal insufficiency (due to prostatic obstruction); large
bladder diverticula or stones; detrusor failure; previous
history of acute urinary retention; current severe, signifi-
cant, or uncontrolled disease; bleeding disorder such as
haemophilia, clotting factor deficiency, anticoagulation, or
bleeding diathesis; hypersensitivity or contraindication to
tamsulosin use; mental condition or disorder that would
interfere with the patient’s ability to provide informed
consent; participation in a study of any investigational drug
or device in the previous 3mo; and administration of the 5-
ARIs finasteride and dutasteride in the previous 6 and 3mo,
respectively. The latter criterion was changed by a protocol
amendment to the administration of the 5-ARIs finasteride
and dutasteride in the previous 2 wk and 4mo, respectively
(these patients may be included if they stop those
medications and replace them for tamsulosin, alfuzosin,
or silodosin for at least 2 wk and 4 mo, respectively).
2.3. Procedures
The patients were evaluated in a screening visit. After
signing the informed consent, urinalysis, uroculture, serum
creatinine, bladder ultrasonography, TRUS, and pelvic
magnetic resonance imaging (MRI) to assess PV were
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tion was stopped and the patients were re-evaluated 2 wk
later for eligibility in a baseline visit. In cases of suspected
prostate cancer, 12-core prostate biopsy was performed. If
the patient remained eligible, the following medications
were prescribed and continued for 7d: omeprazole 20 mg
once daily, and naproxen 1000 mg and ciprofloxacin 500 mg
twice a day. For ethical reasons, tamsulosin 0.4 mg once
daily was administered until LUTS were controlled. A
protocol amendment allowed the prescription of alfuzosin
or silodosin in order to complywith patient preferences, but
in the end, all patients were prescribed tamsulosin. The
decision to stop tamsulosin was made by the study
physician, who evaluated the patient by phone calls on
days 1, 7, and 14 after PAE, and in clinic visits at months 1, 3,
and 6, and was based on a reduction of the IPSS by more
than three points and the QoL score bymore than one point.
PAE was scheduled to the following 2 d, and the patients
were admitted to the hospital 2 h before and discharged 3–
5 h after the procedure.
The medication during the procedure, catheterisation of
the prostatic arteries, and embolisation have been de-
scribed elsewhere [17,19,26] and are detailed in the
Supplementary material. After identifying the left prostatic
arteries, a road map was obtained with the catheter at the
origin of the artery from which these arteries originate. If
this examination confirmed that the anatomy of prostatic
arteries shown by angio-CT and catheterisation of at least
one prostatic artery was possible, the patient was then
randomised to the PAE group or the sham procedure group
in a 1:1 ratio. A randomisation list consisting of permuted
blocks of size varying between 4 and 8 was prepared by the
trial biostatistician (A.G.O.), and the allocation sequence
was concealed using opaque envelopes numbered sequen-
tially. Patients were blinded to the intervention received
until the end of single-blind period.
In the PAE group, Bead Block (BTG plc, London, UK) 300–
500 mmwas used; in the sham group, after catheterisation
of one prostatic artery, the catheter was removed and no
particles were injected, but there was a wait of some
minutes before the removal of the catheter in order to avoid
revealing the treatment arm to patients of the sham group.
All procedures were performed by five interventional
radiologists with 10 yr (J.M.P. and T.B.), 5 yr (N.V.C.), and
3 yr (D.T. and J.P.) of experience in PAE.
Thereafter, the patients were evaluated in clinic visits at
months 1, 3, and 6. At month 1, PV and degree of ischaemia
were evaluated by pelvic MRI. Medications that might
interfere with the evaluation of efficacy variables, such as
psychotherapy, medications prescribed for overactive blad-
der,male hormonal replacement, andmedication that could
induce urinary retention and known to interact with
tamsulosin, were not allowed. A full account of the
forbidden medication is presented in the Supplementary
material. Adverse events (AEs) were recorded at each study
visit and graded according to the Clavien-Dindo classifica-
tion.
At month 6, after the final visit of the single-blind study
period, the patients entered a 6-mo open extension period.The patients who had been randomised to the sham group
were then submitted to PAE with exactly the same
procedure and were evaluated by the same methods at 7,
9, and 12 mo after randomisation. The patients randomised
to PAE continued under observation and had a final study
visit at month 12.
2.4. Outcomes
The coprimary efficacy variables were the change from
baseline to 6 months in the IPSS and the QoL score at 6 mo.
The secondary outcomes were the BPH Impact Index, the
15-item International Index of Erectile Function (IIEF-15),
PV assessed with TRUS, Qmax, PVR, and PSA. Procedure
variables were procedure and fluoroscopy times, radiation
dose, and painmeasuredwith a visual analogue scale from0
(no pain) to 10 (worst pain) during the procedure, at
discharge, and the next morning.
2.5. Statistical analysis
For sample size calculations, the standard deviation of the
change from baseline of the IPSS in a previous prospective
study of 300 PAE was 7.4. With 40 patients per study group,
the clinical trial would be powered to 85% to show, at the
two-sided 0.05 level, a difference of five points in change of
the IPSS from baseline between groups. This difference has
been reported to correspond to the perception of a slight to
moderate improvement in IPSS by LUTS/BPH patients [27].
Data analysis was performed by the intention-to-treat
principle for all randomised patients. Themain analysis was
between-group comparison of the coprimary outcomes at
month 6. In patients who did not complete the trial, missing
data were imputed by the last observation carried forward.
The between-group difference in the change from baseline
in the IPSS was tested at the two-sided 5% level, with
analysis of covariance with the baseline IPSS as a covariate.
The between-group difference in the mean QoL score at
month 6, the coprimary efficacy variable, was compared
with the Student's t test. In order to control the overall alpha
error at the 5% significance level, a serial gatekeeper
procedure was adopted [28]: the primary efficacy variable
would be tested at the 5% significance level, and if the null
hypothesis was rejected, then the coprimary efficacy
variable would be tested also at the 5% significance level;
otherwise, no further significance tests would be per-
formed. If both tests were significant, the study would
conclude for a statistical difference in both primary efficacy
variables at the nominal p value.
Between-group comparisons of the change from base-
line in each secondary efficacy variablewere also performed
with analysis of covariance, with the p values and 95%
confidence intervals (CIs) corrected for multiple compar-
isons with the Bonferroni procedure. To control for the
administration of tamsulosin during the trial, generalised
estimation equations with robust variance estimates and
the assumption of an unstructured correlation structure
were used for between-group comparison of each efficacy
variable over time, adjusting for the number of days
[(Fig._1)TD$FIG]
Fig. 1 – CONSORT diagram. ARI = alphareductase inhibitor; IPSS = International Prostate Symptom Score; PAE = prostatic artery embolisation;
PV = prostate volume; QoL = quality of life.
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Differences between groups in efficacy variables at
12 mo were tested with the Student's t test. Evidence of
statistical significance was considered when p values
were < 0.05. Stata 15 (Stata Corp., College Station, TX, USA)
was used for all analyses.
3. Results
From 2 September 2014 to 3 March 2018, 80 patients with
severe LUTS/BPH refractory to medical therapy with alpha
blockers for at least 6mowere enrolled into the study. Forty
patients were randomised to each trial arm. No patient was
excluded due to difficult vascular situations during the
catheterisation. In the trial single-blind period, one patientin each group was lost to follow-up after months 1 and
3. One patient of the sham group died after month 1 from
acute cholecystitis with sepsis, which was considered not
related to the procedure. In the open extension period, one
patient from the sham group dropped out from the study
after month 7 (Fig. 1). No patient was prematurely
discontinued because of clinical failure or complications
of the disease. There were no protocol deviations due to
missing study visits, administration of forbidden medica-
tion, or other reasons.
The study population had a mean age of 63.8  6.0 yr
(range 48–76 yr), a baseline IPSS of 26.4  3.87 (range 20–
33), a QoL score of 4.43  0.52 (range 3–5), PV by TRUS of
79.5  39.1 cm3 (range 40–235 cm3) and by MRI of
81.6  41.2 cm3 (range 30–260 cm3), and a Qmax of
Table 1 – Baseline patient characteristics.
Variable Sham group PAE group
Median Q1–Q3 Median Q1–Q3
Patient data
Age (yr) 64 60–68.5 64 59.0–67.5
BMI (kg/m2) 26.9 25.5–27.9 26.1 24.5–29.8
Creatinine serum (mg/dl) 0.87 0.70–0.96 0.88 0.77–0.96
Outcome variables
IPSS 27.5 24.0–30.5 25.5 22.5–29.0
QoL 4.5 4.0–5.0 4.0 4.0–5.0
BPH-II 10.0 8.5–11.0 10.0 8.0–11.5
PSA (ng/dl) 3.10 1.59–3.71 3.04 1.54–5.15
Qmax (ml/s) 7.30 4.90–9.40 7.90 5.55–10.2
PVR (ml) 106 60–178 119 72–155
PV (TRUS), cm3 66.0 55.5–94.5 63.5 55.5–100.0
PV (MRI), cm3 66.5 50.0–101.5 68.5 58.0–103.5
IIEF-15 46.0 22.0–52.5 52.5 40.0–61.0
Procedure data
Procedure time (min) 30 30–45 75 60–90
Fluoroscopy time (min) 2.0 1.0–5.7 15.0 12.0–24.8
Radiation dose (Gy.cm2) 102.8 60.5–135.2 201.5 130.0–335.6
BMI = body mass index; BPH-II = Benign Prostate Hyperplasia Impact Index; IIEF-15 = 15-item International Index of Erectile Function; IPSS = International
Prostate Symptom Score; MRI = magnetic resonance imaging; PAE = prostatic artery embolisation; PSA = prostate-specific antigen; PV = prostate volume;
PVR = postvoid residual urine volume; Q1 = first quartile; Q3 = third quartile; Qmax = maximum urinary flow rate; QoL = quality of life; TRUS = transrectal
ultrasonography.
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the baseline characteristics (Table 1). PAEwas bilateral in all
but three (7.5%) patients.
The change over time in the two study periods is shown
in Figure 2 for the subjective outcomes and in Figure 3 for[(Fig._2)TD$FIG]Fig. 2 – Mean values over time after prostatic artery embolisation and a sham
second period, patients in the sham group were submitted to PAE. Solid circle
error bars represent 95% confidence intervals. The numbers are the mean valu
BPH = benign prostatic hyperplasia; PAE = prostatic artery embolisation.the functional outcomes. The decrease from baseline to
month 6 in IPSS was 5.03  8.13 in the sham group and
17.1 7.25 in the PAE group (difference between groups of
changes from baseline: 13.2, 95% CI 10.2–16.2, p < 0.0001).
At month 6, the mean IPSSs were 21.9  7.34 in the shamprocedure in the subjective outcomes in the two study periods. In the
s represent the PAE group, open circles represent the sham group, and
es observed at each study visit. AUA = American Urological Association;
[(Fig._3)TD$FIG]
Fig. 3 – Mean values over time after prostatic artery embolisation and a sham procedure in the functional outcomes in the two study periods. In the
second period, patients in the sham group were submitted to PAE. Solid circles represent the PAE group, open circles represent the sham group, and
error bars represent 95% confidence intervals. The numbers are the mean values observed at each study visit. PAE = prostatic artery embolisation.
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scores at month 6 were 3.48  1.38 and 1.35  1.12 in the
sham and PAE groups (difference in themeans of QoL scores
between groups at month 6: 2.13, 95% CI 1.57–2.68,
p < 0.0001), respectively, corresponding to decreases from
baseline of 1.03  1.19 and 3.00  1.13, respectively (-
p < 0.0001).
In the secondary efficacy variables, there was greater
improvement, both statistically and clinically significant,
in Benign Prostate Hyperplasia Impact Index score and in
all functional outcomes. There was no evidence of
worsening of the IIEF-15 score. In the PAE group, between
baseline and 12mo, the mean Qmax increasewas 5.96 ml/s
(95% CI 3.95–7.97 ml/s, p < 0.0001), while between
months 6 and 12, there was no statistically significant
change (95% CI –2.49 to 0.49 ml/s, p = 0.18). Table 2
presents the results for all efficacy variables. In the sham
group, 34 (91.9%) patients were still taking tamsulosin at
the end of the main study, compared with only two (5.13%)
in the PAE group (p < 0.0001). The average number of days
under tamsulosin medication was 184  38 in the sham
group and 38  52 in the PAE group (p < 0.0001).
Controlling of the between-group comparison by the
administration of tamsulosin did not change the results:
the average between-group differences at each time point
throughout the study period were 9.56 (95% CI 6.79–12.3,
p < 0.001) in the IPSS and 1.33 (95% CI 0.75–1.91, p < 0.001)
in the QoL score.PAE was performed in all 38 patients of the sham group
who completed the single-blind phase. Procedure data were
not significantly different from those of patients in the PAE
group (procedure time 71.3 18.1 min, fluoroscopy time
19.4  9.71 min, radiation dose 247.9 153.8 Gy.cm2). There
was a statistically significant improvement at the 12-mo
evaluation in all efficacy variables except for IIEF-15. In the
comparisonwith the results at 12mo in the PAE group, there
were no statistically significant differences in any efficacy
variables (unadjusted p values). The 95% CI values of the
between-group difference at 12 mowere 2.3–3.53 (p = 0.66)
in the IPSS and 0.48–0.63 (p = 0.80) in the QoL score.
No patient in the sham group mentioned pain during
PAE, at discharge, or next morning. In the PAE group, no
patient complained of pain during the procedure, two
complained of pain at discharge, and two complained the
next morning. All patients were discharged between 2 and
6 h after PAE.
Therewere 16 AEs in 14 (35.0%) patients in the PAE group
and 17 in 13 (32.5%) patients in the sham group. In the
38 patients of this group who underwent PAE, there were
13 AEs in 11 (28.9%) patients (Table 3). Among the 29 AEs in
the 78 patients whowere submitted to PAE, 25 (86.2%) were
of grade I, three (10.3%) of grade II, and one (3.4%) of grade
IIIa, consisting of expelled small prostate fragments causing
haematuria and acute urinary retention, treated by TURP
and followed by complete recovery without sequelae. Two
patients with dysuria and burning urethral pain, and one
Table 2 – Change from baseline to month 6 after a sham procedure and PAE.
Variable Sham PAE Difference PAE – sham p value
Mean SD Mean SD Mean SD 95% CI
IPSS –5.03 8.13 –17.1 7.25 –13.2 1.50 –16.2 –10.2 <0.0001
QoL –1.03 1.19 –3.00 1.13 –1.99 0.26 –2.51 –1.46 <0.0001
BPH-II –2.28 3.69 –6.33 4.09 –4.28 0.78 –6.49 –2.08 <0.0001a
PSA (ng/dl) –0.02 2.13 –1.51 2.17 –1.22 0.37 –2.27 –0.17 0.01a
Qmax (ml/s) 2.80 4.75 6.82 6.25 4.22 1.19 0.86 7.58 0.005a
PVR (ml) 8.63 127.1 –59.9 109.3 –60.6 19.9 –116.7 –4.6 0.03a
PV (cm3) –0.06 20.9 –17.6 18.5 –16.8 4.38 –29.2 –4.52 0.002a
IIEF-15 5.95 18.7 9.53 15.4 7.28 3.41 –2.32 16.9 0.29a
BPH-II = Benign Prostate Hyperplasia Impact Index, a four-item self-administered questionnaire measuring how LUTS affect four key domains (physical
discomfort, worry about health, bother, and impact on usual activities) scored from 0 to 13 points, with lower scores indicating less important symptoms;
CI = confidence interval; IIEF-15 = International Index of Erectile Function, a 15-item self-administered questionnaire with a total score from 0 to 75, with lower
values indicating more severe erectile dysfunction, which evaluates the four main domains of male sexual function (erectile function, orgasmic function, sexual
desire; and intercourse satisfaction); IPSS = International Prostate Symptom Score, a seven-item self-administered questionnaire with a total score ranging from
0 to 35, higher scores indicating more severe LUTS; LUTS = lower urinary tract symptoms; PAE = prostatic artery embolisation; PSA = prostate-specific antigen;
PV = prostate volume by transrectal ultrasonography; PVR = postvoid residual urine volume; Qmax = maximum urinary flow rate; QoL = the eighth question in
the IPSS measuring disease-specific quality of life from 0 to 6, with higher scores indicating worse quality of life; SD = standard deviation.
a p values and 95% confidence intervals adjusted for multiple comparisons.
Table 3 – Adverse events.
Adverse event After sham After PAE
(n = 40) PAE group (n = 40) Sham group (n = 38) Total (n = 78)
Number with adverse event 13 (32.5) 14 (35.0) 11 (28.9) 25 (32.1)
Burning perineal pain 1 (2.5) 1 (1.3)
Burning urethral pain 2 (5.0) 2 (5.0) 1 (2.6) 3 (3.8)
Dysuria 2 (5.0) 1 (2.5) 2 (5.3) 3 (3.8)
Ecchymosis 9 (22.5) 2 (5.0) 2 (2.6)
Haematospermia 3 (7.5) 4 (10.5) 7 (9.0)
Haematuria 2 (5.0) 3 (7.5) 2 (5.3) 5 (6.4)
Inguinal haematoma 3 (7.5) 1 (2.6) 4 (5.1)
Prostate fragment expelled 1 (2.6) 1 (1.3)
Rectorrhagia 2 (5.0) 2 (5.3) 2 (2.6)
Urinary tract infection 1 (2.5) 1 (1.3)
PAE = prostatic artery embolisation.
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treatment; all other AEs subsided spontaneously. Detailed
tables of efficacy variables and AEs are presented in the
Supplementary material.4. Discussion
The single-blind period of this randomised clinical trial fills
the gap in the evidence base on the treatment effect of PAE
by demonstrating both clinically and statistically significant
differences in patients treated with PAE as compared with
patients submitted to a sham procedure. In addition, the
trial open extension period offers evidence of sustainability
of effects up to 12 mo.
PAE is considered experimental in the urology guidelines
[11,12]. For a novel technique such as PAE to be considered
as a first-line option, sham-controlled trials are very helpful,
and hence the present study. Randomised trials with a long-
term follow-up comparing PAE and surgery and medicaltherapy are also important to better understand the role of
PAE in the management of patients with LUTS/BPH.
The results of this randomised clinical trial provide clear
evidence that the improvement experienced by patients
after PAE is due to a real treatment effect that is much
larger than the placebo effect associated with the
procedure. The marked and sustained amelioration in all
primary and secondary outcomes, with no negative
influence on erectile function, offers strong evidence that
PAE, through the reduction it imposes on prostate size and
possibly because of several other mechanisms, actually
modifies the course of LUTS/BPH, and this explains the
high clinical success rates reported so far with this
treatment. The results in this study, which included a 2-
wk period for the wash-out of alpha-blockers, are clearly
better than the results of the trials where drugs were
stopped only after PAE had been performed, and this may
explain the different results.
PAE ismostly painless and safe, withmost AEs beingmild
and self-limited. A serious event consisting of expelled
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no sequels. Others have reported a similar AE in up to 6% of
patients after PAE [29–31].
The main limitation of this study was the inclusion of
patients with severe LUTS only, as less symptomatic patients
may have less pronounced improvement compared with
placebo. In addition, the average prostate size of the study
participants was rather large (81.6 cm3), and as larger PVs
have been shown by some to correlate with better outcomes
after PAE [31], the results from this trial may not be
generalisable for prostates smaller than 40 cm3, which have
been reported to showaworse response to PAE [32]. The trial
was conducted at a clinical centre with extensive experience
inPAE, andwith less skilledoperators the resultsmaydiverge
somewhat, althoughconsidering the consistencyof results of
PAE reported by other authors, we would not expect any
appreciable difference fromour results [17,20–22]. The 6-mo
single-blindperiod is justifiedbecause itmight not be ethical
to withhold treatment for a longer time in patients with
severe LUTS refractory tomedical treatmentandalso for fears
of patient attrition in the shamgroup in a long-term trial.We,
however, followedupthepatients fora furtheropenperiodof
6 mo during which we have shown no regression of the
effects observed after PAE. Moreover, for ethical reasons,
randomisation was performed only after confirmation by
catheterism that PAE was feasible; otherwise, patients
randomised to the sham arm in whom catheterism proved
to be unsuccessful would have to be deceived for 6 mo into
believing that after the 6-mo open period they would have
access to PAE. Technical failures are uncommon because of
the preprocedure protocol that we follow, and actually no
patient was excluded for that reason.
Major questions still remain regarding the durability of
the treatment effect, especially considering a lower impact
when compared with surgery on objective parameters such
as PV reduction and relief of the bladder outlet obstruction
[25]. Noninferiority clinical trials providing data on long-
term outcomes after PAE in large patient cohorts are needed
to critically assess these issues. Future research should focus
on providing comparative studies of PAE with surgery or
medical care with appropriate cohort sizes and long-term
follow-up. PAE alongside with prostatic urethral lift and
water vapour thermal therapy is less invasive than surgery
and, thus,might be justified instead ofmedical treatment, or
in patients between medical treatment and surgery on their
pathway of care. TURP and other endoscopic treatment
options that remove tissue might be the best option in
patients who require maximum relief of bladder outlet
obstruction. Moreover, further efforts should be made to
identify the ideal candidates for PAE. The results of this
clinical trial will be a reference for future research consensus
panels and guidelines on the management of LUTS/BPH.
5. Conclusions
In conclusion, the improvements in subjective and objective
variables after PAE are far superior to those due to the
placebo effect, and the results of this single-blind random-
ised clinical trial clearly establish PAE as a safe and effectiveminimally invasive treatment for benign prostatic hyper-
plasia, which, combined with the evidence from random-
ised clinical trials comparing PAEwith TURP, support its role
in the treatment of LUTS/BPH. Clinical trials with longer
follow-up and noninferiority trials of PAE versus other
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